Relay Therapeutics ( RLAY ) Upgraded to Buy: What Does It Mean for the Stock?
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Relay Therapeutics, Inc. ( RLAY ) Reports Q2 Loss, Beats Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.33% and +35.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Relay ( RLAY ) Q2 Loss Narrows 41%
Relay Therapeutics ( NASDAQ:RLAY ) , a clinical-stage biotechnology company focused on developing precision medicines through computational drug discovery, released its second-quarter 2025 results on August 7, 2025. The key news from the period was a beat on both top and bottom lines ( GAAP ) .
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
RXRX gains 5.5% in a month on positive pipeline update. long-term hold advised given strong potential of its AI-driven drug discovery platform.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire ...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Relay Therapeutics ( NASDAQ:RLAY ) , Bicara Therapeutics ( NASDAQ:BCAX )
CAMBRIDGE, Mass., June 11, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. RLAY, a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, ...
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 - Relay Therapeutics ( NASDAQ:RLAY )
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer ...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - Relay Therapeutics ( NASDAQ:RLAY )
CAMBRIDGE, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. RLAY, a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two ...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will ...
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
What Makes Relay Therapeutics ( RLAY ) a New Buy Stock
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
CAMBRIDGE, Mass., April 28, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial ...
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Bicara Therapeutics ( NASDAQ:BCAX ) , Amkor Tech ( NASDAQ:AMKR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics ( RLAY )
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will ...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
CAMBRIDGE, Mass., Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year ...
Relay Therapeutics ( RLAY ) Moves to Buy: Rationale Behind the Upgrade
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - Relay Therapeutics ( NASDAQ:RLAY )
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at ...
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - Relay Therapeutics ( NASDAQ:RLAY )
CAMBRIDGE, Mass., Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc.
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Company to host conference call on Wednesday, December 11, 2024 at 7am ET Company to host conference call on Wednesday, December 11, 2024 at 7am ET ...
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics ( RLAY )
Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - Relay Therapeutics ( NASDAQ:RLAY )
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib ( RLY-4008 ) Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable ...
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize ...
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics ( RLAY ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics ( RLAY ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Stevanato Group ( STVN ) Q3 Earnings Match Estimates
Stevanato (STVN) delivered earnings and revenue surprises of 0% and 1.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - Relay Therapeutics ( NASDAQ:RLAY )
CAMBRIDGE, Mass., Oct. 30, 2024 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc.
EQS-News: BB Biotech: Strategic reallocation of portfolio assets progressing
BB Biotech: Strategic reallocation of portfolio assets progressing Portfolio of BB Biotech AG as at September 30, 2024 A key event during the period under review was the US Federal Reserve's decision in September to lower interest rates by 50 bps, marking its first rate cut in four years.
Strength Seen in Relay Therapeutics ( RLAY ) : Can Its 6.7% Jump Turn into More Strength?
Relay Therapeutics (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
Why Relay Therapeutics Plummeted by Nearly 14% Today
Investors weren't happy with the company's latest effort at capital-raising.
Why Relay Therapeutics ( RLAY ) Stock Is Down 17% Today - Relay Therapeutics ( NASDAQ:RLAY )
Relay Therapeutics Inc RLAY shares are trading lower by 17.8% to $7.40 during Wednesday's session after the company priced its $200 million offering. The offering of 28.57 million shares of common stock at $7.00 per share is expected to raise approximately $200 million before fees.
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - GameStop ( NYSE:GME )
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Wednesday. Shares of GameStop Corp. GME fell sharply in today's pre-market trading following second-quarter results.
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Dave & Buster's Enter ( NASDAQ:PLAY )
Shares of Dave & Buster's Entertainment, Inc. PLAY rose sharply in today's pre-market trading after the company posted stronger-than-expected earnings for its second quarter on Tuesday. Dave & Buster's reported quarterly earnings of $1.12 per share, which beat the analyst consensus estimate of 84 ...
Relay Therapeutics Announces Pricing of Public Offering of Common Stock - Relay Therapeutics ( NASDAQ:RLAY )
CAMBRIDGE, Mass., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Relay Therapeutics, Inc. ( Nasdaq: RLAY ) , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an ...
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market - Relay Therapeutics ( NASDAQ:RLAY )
Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib ( Pfizer Inc's PFE selective CDK4 inhibitor ) .
Relay Stock Soars on Upbeat Data From Breast Cancer Study
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Johnson Controls Intl ( NYSE:JCI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone - NVIDIA ( NASDAQ:NVDA )
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, but the index remained in the "Fear" zone on Monday. U.S. stocks settled higher on Monday, with the Dow Jones index surging more than 1% during the session after losing over 1,200 points last week.
